1. 4BA A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC). (September 2015) Authors: Carducci, M.; Armstrong, A.; Pili, R.; Ng, S.; Huddart, R.; Agarwal, N.; Khvorostenko, D.; Lyulko, O.; Brize, A.; Vogelzang, N.J.; Delva, R.; Harza, M.; Thanos, A.; James, N.; Werbrouck, P.; Bögemann, M.; Hutson, T.; Milecki, P.; Nederman, T.; Sternberg, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S713 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗